West Acquires Drug Delivery Assets From Plastef Investissements SA

LIONVILLE, Pa., July 7 /PRNewswire-FirstCall/ -- West Pharmaceutical Services,
Inc. (NYSE: WST) today announced that it has purchased the drug delivery
device business assets of Plastef Investissements SA. Under the agreement West
has obtained the right to manufacture the eris safety syringe, a passive
safety system for use with fixed, or staked, needle prefillable syringes.
Operations will continue at Plastef's production facility located in Le
Vaudreuil, Normandy, France, which has approximately 75 employees.

The eris system for staked needle syringes complements West's NovaGuard(TM)
passive safety needle, which it recently introduced to the market for use with
luer-lock syringes.

Financial terms of the transaction were not disclosed. The acquisition is
expected to increase West's sales revenue by an estimated $5 million to $7
million over the remainder of 2009, and the acquisition is not expected to
materially affect the Company's fully diluted earnings per share this year.

About West
West is a global manufacturer of components and systems for injectable drug
delivery, including stoppers and seals for vials, and closures and disposable
components used in syringe, IV and blood collection systems. The Company also
provides products with application to the personal care, food and beverage
markets. Headquartered in Lionville, Pennsylvania, West supports its partners
and customers from 50 locations throughout North America, South America,
Europe, Mexico, Japan, Asia and Australia. For more information, visit West at
www.westpharma.com.

Contacts: Investors and Financial Media:
West FD
Michael A. Anderson Evan Smith / Theresa Kelleher
Vice President and Treasurer (212) 850-5600
(610) 594-3345 wst@fd.com

SOURCE West Pharmaceutical Services, Inc.

Michael A. Anderson, Vice President and Treasurer, West, +1-610-594-3345,
Investors and Financial Media: Evan Smith, or Theresa Kelleher, both of FD,
+1-212-850-5600, wst@fd.com